Biomarker Modeling of Alzheimer's Disease

Overview

Journal Neuron

Publisher Cell Press

Specialty Neurology

Date 2013 Dec 24

PMID 24360540

Citations 443

Authors

Clifford R Jack Jr

David M Holtzman

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.

Citing Articles

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.

Thal D, Poesen K, Vandenberghe R, De Meyer S Mol Neurodegener. 2025; 20(1):33.

PMID: 40087672 DOI: 10.1186/s13024-025-00819-y.

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.

Leuzy A, Bollack A, Pellegrino D, Teunissen C, La Joie R, Rabinovici G Alzheimers Dement. 2025; 21(3):e14528.

PMID: 40042435 PMC: 11881640. DOI: 10.1002/alz.14528.

Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis.

Coughlan G, Klinger H, Boyle R, Betthauser T, Binette A, Christenson L JAMA Neurol. 2025; .

PMID: 40029638 PMC: 11877413. DOI: 10.1001/jamaneurol.2025.0013.

Exposure to Manganese Induces Autophagy-Lysosomal Pathway Dysfunction-Mediated Tauopathy by Activating the cGAS-STING Pathway in the Brain.

Zhang X, Liu J, Zhong S, Zhang Z, Zhou Q, Yang J Environ Health (Wash). 2025; 3(2):199-212.

PMID: 40012869 PMC: 11851216. DOI: 10.1021/envhealth.4c00176.

Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window.

Yakoub Y, Gonzalez-Ortiz F, Ashton N, Dery C, Strikwerda-Brown C, St-Onge F Alzheimers Dement. 2025; 21(2):e14537.

PMID: 40008832 PMC: 11863240. DOI: 10.1002/alz.14537.

References

Tarawneh R, DAngelo G, Macy E, Xiong C, Carter D, Cairns N . Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011; 70(2):274-85. PMC: 3154071. DOI: 10.1002/ana.22448. View

Duyckaerts C . Tau pathology in children and young adults: can you still be unconditionally baptist?. Acta Neuropathol. 2011; 121(2):145-7. DOI: 10.1007/s00401-010-0794-7. View

Knopman D, Parisi J, Salviati A, Floriach-Robert M, Boeve B, Ivnik R . Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003; 62(11):1087-95. DOI: 10.1093/jnen/62.11.1087. View

Fox N, Black R, Gilman S, Rossor M, Griffith S, Jenkins L . Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005; 64(9):1563-72. DOI: 10.1212/01.WNL.0000159743.08996.99. View

Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

Visser P, Verhey F, Knol D, Scheltens P, Wahlund L, Freund-Levi Y . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8(7):619-27. DOI: 10.1016/S1474-4422(09)70139-5. View

Jack Jr C, Wiste H, Weigand S, Knopman D, Lowe V, Vemuri P . Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013; 81(20):1732-40. PMC: 3821718. DOI: 10.1212/01.wnl.0000435556.21319.e4. View

Griciuc A, Serrano-Pozo A, Parrado A, Lesinski A, Asselin C, Mullin K . Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013; 78(4):631-43. PMC: 3706457. DOI: 10.1016/j.neuron.2013.04.014. View

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

10.

Naj A, Jun G, Beecham G, Wang L, Vardarajan B, Buros J . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011; 43(5):436-41. PMC: 3090745. DOI: 10.1038/ng.801. View

11.

Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

12.

Wolk D, Price J, Madeira C, Saxton J, Snitz B, Lopez O . Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012; 8(5):389-98. PMC: 3517915. DOI: 10.1016/j.jalz.2011.07.003. View

13.

Oddo S, Caccamo A, Kitazawa M, Tseng B, LaFerla F . Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003; 24(8):1063-70. DOI: 10.1016/j.neurobiolaging.2003.08.012. View

14.

Reiman E, Quiroz Y, Fleisher A, Chen K, Velez-Pardo C, Jimenez-Del-Rio M . Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012; 11(12):1048-56. PMC: 4181671. DOI: 10.1016/S1474-4422(12)70228-4. View

15.

Drzezga A . Amyloid-plaque imaging in early and differential diagnosis of dementia. Ann Nucl Med. 2010; 24(2):55-66. DOI: 10.1007/s12149-009-0330-9. View

16.

Johnson K, Gregas M, Becker J, Kinnecom C, Salat D, Moran E . Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62(3):229-34. DOI: 10.1002/ana.21164. View

17.

Price J, Morris J . Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999; 45(3):358-68. DOI: 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x. View

18.

Rabinovici G, Jagust W, Furst A, Ogar J, Racine C, Mormino E . Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008; 64(4):388-401. PMC: 2648510. DOI: 10.1002/ana.21451. View

19.

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View

20.

Chien D, Bahri S, Szardenings A, Walsh J, Mu F, Su M . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2012; 34(2):457-68. DOI: 10.3233/JAD-122059. View